Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors

Fig. 5

The effect that route of pixatimod administration has on the activation of NK cells. a Mice were dosed with 400 μg (20 mg/kg) of pixatimod intraperitoneally (IP), intravenously (IV) or subcutaneously (SC) and after 2 days the activation status of NK cells (CD3−, NK1.1+) isolated from spleens were assessed. b The percentage of NK cells positive for CD69 and IFN-γ are plotted. The gating for CD69 and IFN-γ positive NK cells is shown in panel a

Back to article page